Syros Pharmaceuticals, Inc.
US ˙ OTCPK ˙ US87184Q2066

Introduction

This page provides a comprehensive analysis of the known insider trading history of Peter Wirth. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Peter Wirth has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ZLAB / Zai Lab Limited - Depositary Receipt (Common Stock) Director 393,750
US:SYRS / Syros Pharmaceuticals, Inc. Director 16,000
US:FMTX / Forma Therapeutics Holdings Inc Director 0
US:GEVA / Synageva Biopharma Corp Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Peter Wirth. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases SYRS / Syros Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in SYRS / Syros Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Sales SYRS / Syros Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in SYRS / Syros Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Peter Wirth as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-23 2025-06-18 4 ZLAB Zai Lab Ltd
American Depositary Shares
A - Award 10,831 393,750 2.83
2024-06-20 2024-06-18 4 ZLAB Zai Lab Ltd
American Depositary Shares
A - Award 21,253 382,919 5.88
2024-06-07 2024-06-05 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
A - Award 4,000 16,000 33.33
2023-06-30 2023-06-29 4 ZLAB Zai Lab Ltd
American Depositary Shares
A - Award 18,903 361,666 5.51 26.45 499,984 9,566,066
2023-06-02 2023-06-01 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
A - Award 4,000 12,000 50.00
2022-12-12 2021-12-08 4/A ZLAB Zai Lab Ltd
American Depositary Shares
P - Purchase 4,000 4,000 71.36 285,440 285,440
2022-12-09 2022-12-08 4 ZLAB Zai Lab Ltd
American Depositary Shares
S - Sale -4,000 0 -100.00 35.33 -141,320
2022-12-09 2022-12-08 4 ZLAB Zai Lab Ltd
American Depositary Shares
S - Sale -3,852 342,763 -1.11 35.37 -136,245 12,123,527
2022-10-14 2022-10-14 4 FMTX Forma Therapeutics Holdings, Inc.
Common Stock
U - Other -7,250 0 -100.00
2022-10-14 2022-10-14 4 FMTX Forma Therapeutics Holdings, Inc.
Common Stock
U - Other -127,665 0 -100.00
2022-09-19 2022-09-16 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
A - Award 8,000 8,000
2022-06-09 2022-06-08 4 FMTX Forma Therapeutics Holdings, Inc.
Common Stock
A - Award 4,500 134,915 3.45
2022-01-04 2022-01-03 4 ZLAB Zai Lab Ltd
Ordinary Shares
A - Award 7,763 350,615 2.26
2021-12-08 2021-12-08 4 ZLAB Zai Lab Ltd
Ordinary Shares
P - Purchase 4,000 342,852 1.18 71.36 285,440 24,465,919
2021-06-21 2021-06-17 4 FMTX Forma Therapeutics Holdings, Inc.
Stock Option (Right to Buy)
A - Award 8,375 8,375
2021-06-21 2021-06-17 4 FMTX Forma Therapeutics Holdings, Inc.
Common Stock
A - Award 2,750 130,415 2.15
2021-06-10 2021-06-08 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 17,500 17,500
2021-01-20 2021-01-15 4 ZLAB Zai Lab Ltd
Ordinary Shares
A - Award 3,852 338,852 1.15
2021-01-19 3/A ZLAB Zai Lab Ltd
Ordinary Shares
35,000
2021-01-19 3/A ZLAB Zai Lab Ltd
Ordinary Shares
335,000
2021-01-04 3 ZLAB Zai Lab Ltd
Ordinary Shares
335,000
2020-06-24 2020-06-23 4 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 5 Junior Stock
S - Sale -14,026 0 -100.00
2020-06-24 2020-06-23 4 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 4 Junior Stock
S - Sale -10,240 0 -100.00
2020-06-24 2020-06-23 4 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 3 Junior Stock
S - Sale -9,847 0 -100.00
2020-06-24 2020-06-23 4 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 2 Junior Stock
S - Sale -18,585 0 -100.00
2020-06-24 2020-06-23 4 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 1 Junior Stock
S - Sale -25,756 0 -100.00
2020-06-24 2020-06-23 4 FMTX Forma Therapeutics Holdings, Inc.,
Common Stock
P - Purchase 63,299 127,665 98.34
2020-06-22 2020-06-18 4 FMTX Forma Therapeutics Holdings, Inc.,
Stock Option (Right to Buy)
A - Award 17,533 0 -100.00
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Common Stock
189,366
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 1 Junior Stock
147,744
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 2 Junior Stock
139,605
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 3 Junior Stock
132,325
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 4 Junior Stock
132,332
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 5 Junior Stock
133,628
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Common Stock
189,366
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 1 Junior Stock
147,744
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 2 Junior Stock
139,605
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 3 Junior Stock
132,325
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 4 Junior Stock
132,332
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 5 Junior Stock
133,628
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Common Stock
189,366
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 1 Junior Stock
147,744
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 2 Junior Stock
139,605
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 3 Junior Stock
132,325
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 4 Junior Stock
132,332
2020-06-18 3 FMTX Forma Therapeutics Holdings, Inc.,
Enterprise 5 Junior Stock
133,628
2020-06-11 2020-06-11 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 17,500 17,500
2019-06-12 2019-06-11 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 11,000 11,000
2018-06-15 2018-06-14 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 11,000 11,000
2017-01-30 2017-01-27 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 22,000 22,000
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -7,500 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -7,500 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -15,000 0 -100.00
2014-06-05 2014-06-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 7,500 7,500
2013-06-10 2013-06-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 7,500 7,500
2012-06-29 2012-06-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 15,000 15,000
2012-06-29 3 GEVA SYNAGEVA BIOPHARMA CORP
No securities beneficially owned
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)